RxDoctor Payments Data

Juan Arraut, MD

Internal Medicine · Hato Rey, PRNPI 1487852299

Payments from drug & device makers

$5,084in general payments, 2019–2025

Across 257 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$578
  • Boehringer Ingelheim$495
  • Johnson & Johnson$465
  • PBG Puerto Rico LLC$329
  • Amgen$276
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,075100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,084 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$38,390
Medicare patients
128
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$105,499
JardianceEmpagliflozin51$72,966
CreonLipase/Protease/Amylase12$69,126
XareltoRivaroxaban57$67,775
EliquisApixaban59$59,088
SynthroidLevothyroxine Sodium387$49,408
Synjardy XrEmpagliflozin/Metformin Hcl39$49,067
JanuviaSitagliptin Phosphate22$34,211
OzempicSemaglutide24$30,642
SynjardyEmpagliflozin/Metformin Hcl28$29,978
JanumetSitagliptin Phos/Metformin Hcl19$25,531
Janumet XrSitagliptin Phos/Metformin Hcl17$20,763
Xigduo XrDapaglifloz Propaned/Metformin14$18,536
Trijardy XrEmpaglifloz/Linaglip/Metformin11$16,532
LantusInsulin Glargine,hum.Rec.Anlog143$13,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Trijardy Xr$495$168,543129 claims
AbbVieCreon, Synthroid$188$118,534399 claims
AstraZenecaFarxiga$1,636$105,49999 claims
MerckJanuvia, Janumet, Janumet Xr, Lagevrio (Eua)$222$88,14569 claims
Johnson & JohnsonXarelto$465$67,77557 claims
Novo NordiskOzempic$578$30,64224 claims
Sanofi-aventis U.S. LLCLantus$175$13,851143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Hato Rey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →